Engrail Therapeutics is a pharmaceutical company focused on developing precision-targeted therapies striving to transform the lives of patients suffering from severe and life-limiting neurological, neuropsychiatric, and neurodevelopmental disorders. The company is seeking to leverage scientific insights into molecular mechanisms and neurocircuitry with the goal of advancing the development of novel treatments aimed at addressing unmet medical needs. Engrail Therapeutics was founded by Stephen Cunningham and Vikram Sudarsan in 2019 and is headquartered in San Diego, CA.
Engrail Therapeutics is a privately held company and is not publicly traded, therefore investing in Engrail Therapeutics pre-IPO is only available to accredited investors. If you meet the accreditation criteria, you can learn more about Forge’s Secondary Marketplace and how to invest in private companies before their potential IPO. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.
Can you sell shares of Engrail Therapeutics before it goes public?
You can seek to sell your shares in Engrail Therapeutics while it remains private. If you are considering selling, you can register today for free to get started. Once registered, a Private Market Specialist will guide you through any questions you might have. You may also continue to browse through our resources to help you understand the implications and procedures involved in selling your private market shares.
What is the pre-IPO value of my Engrail Therapeutics shares?
To determine the value of your Engrail Therapeutics shares, create a free account to gain access to Forge’s platform. In addition to the Forge Price, Forge Markets contains pricing information for hundreds of pre-IPO companies such as Last Closed Trade Price. A Private Market Specialist will also be available to assist you with any inquiries related to your Engrail Therapeutics shares. You can also learn more about how to sell your private shares before getting started.
Is Engrail Therapeutics a publicly traded company?
If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.
To learn more about Engrail Therapeutics potential IPO
Will Engrail Therapeutics go IPO?
Engrail Therapeutics has not yet filed for an IPO. However, it’s important to note that IPOs are not the sole avenue for a private company to transition to public trading. Private companies can also go public through alternative methods such as but limited to Special Purpose Acquisition Companies (SPACs), direct listings, or mergers and acquisitions. Find out which companies are eyeing an IPO on our Tech IPO Calendar 2024.
What is Engrail Therapeutics’ IPO price?
The Engrail Therapeutics IPO price does not exist at this time, as Engrail Therapeutics is still a private company and has not yet conducted an IPO. To explore secondary market data and access private market pricing details and data that may be related to Engrail Therapeutics register for Forge Markets, today.
When was Engrail Therapeutics founded?
Engrail Therapeutics was founded in 2019.
What is Engrail Therapeutics funding to date?
Engrail Therapeutics has raised $195.08MM to date.
Who are Engrail Therapeutics’s major investors?
Norwest Venture Partners
Eight Roads Ventures
Longwood Fund
F-Prime Capital
Ysios Capital
Red Tree Venture Capital
Pivotal Life Sciences
Forbion
Abrdn
RiverVest Venture Partners
Engrail Therapeutics Funding Rounds and Valuation
Funding History Chart
Funding Round Details
Funding Date
Share Class
Amount Raised
Price per Share
Post-Money Valuation
Key Investors
03/19/2024
Series B-2
$36.56MM
$xx.xx
$263.11MM
F-Prime Capital, Forbion, Norwest Venture Partners, RiverVest Venture Partners, Red Tree Venture Capital, abrdn Inc., Ysios Capital, Longwood Fund, Eight Roads Ventures, Pivotal Life Sciences
Price per Share
$xx.xx
Shares Outstanding
43,151,767
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
F-Prime Capital, Forbion, Norwest Venture Partners, RiverVest Venture Partners, Red Tree Venture Capital, abrdn Inc., Ysios Capital, Longwood Fund, Eight Roads Ventures, Pivotal Life Sciences
03/19/2024
Series B-1
$120.44MM
$xx.xx
$263.11MM
F-Prime Capital, Forbion, Norwest Venture Partners, RiverVest Venture Partners, Red Tree Venture Capital, abrdn Inc., Ysios Capital, Longwood Fund, Eight Roads Ventures, Pivotal Life Sciences
Price per Share
$xx.xx
Shares Outstanding
113,731,655
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
F-Prime Capital, Forbion, Norwest Venture Partners, RiverVest Venture Partners, Red Tree Venture Capital, abrdn Inc., Ysios Capital, Longwood Fund, Eight Roads Ventures, Pivotal Life Sciences
PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES
‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.
Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.
Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.
Forge Investment Outlook Q4 2024
